Optimus Pharma
Optimus Pharma is a Hyderabad-based CDMO delivering integrated contract development and manufacturing of small molecule drug substances and drug products, serving global pharmaceutical and biotech companies across 40+ countries with USFDA-inspected multi-unit facilities.
- Company typePrivate
- Founded2004
- HeadquartersHyderabad, India
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Optimus Pharma does
Optimus Pharma is a Hyderabad-headquartered Contract Development and Manufacturing Organization (CDMO) that delivers integrated, end-to-end services for small molecule drug substances and drug products, operating across four manufacturing units located in Hyderabad and Visakhapatnam (Andhra Pradesh). The platform spans drug substance intermediates, small molecule APIs (including NCE/NDA, custom, and generic), drug product intermediates (pellets, micronized APIs, spray-dried materials), and finished dosage formulations (oral solids, semi-solids, immediate and controlled release). The company serves global pharmaceutical and biotechnology clients — including Pfizer, Teva, Sandoz, Sun Pharma, Cipla, Dr. Reddy's, Aurobindo, Mylan, Biocon, Torrent, Hikma, and Celltrion — across more than 40 countries.
Its technical differentiation rests on a 150+ scientist R&D team at a CSIR-approved center, expertise in complex chemistry (chiral synthesis, Birch, Grignard, Suzuki, Mitsunobu, Wolff-Kishner reductions, and others), and specialty manufacturing capabilities including cGMP-compliant spray drying for amorphous solid dispersions, advanced jet-milled micronization, multi-particulate pellet systems, and nitrosamine / NDSRI impurity detection using XRD, HPLC, LC-MS, and GC-MS. Manufacturing infrastructure totals 822 KL of reactor capacity across the three API/intermediate units, plus a USFDA-inspected Unit 4 FDF facility with annual capacity of 1.6 billion tablets, 400 million capsules, 40+ MT of pellets, and 30+ million tubes.
The business model is B2B contract services revenue combined with API and FDF product sales. Pricing is quote-based and tied to project scope, volume, and complexity. Go-to-market relies on dedicated enterprise field sales, direct client engagement, and a heavy trade-show calendar (DCAT Week, CPHI Worldwide / North America, ChemSpec Europe, Pharmaconex). Ownership sits with Sekhmet Pharmaventures Pvt. Ltd. — part of the Singapore-based Gamot API Pte Ltd. investment platform formed by PAG, CX Partners, and Samara Capital, which acquired a majority stake in May 2022 to consolidate a multi-vertical Indian pharma platform spanning intermediates, API, FDF, and CDMO services. The group operates through three affiliated India-domiciled private limited entities: Optimus Drugs Private Limited, Optimus Pharma Private Limited, and Optimus Life Science Private Limited.
Optimus Pharma firmographics
Firmographics- Name
- Optimus Pharma
- Legal name
- Optimus Drugs Private Limited
- Website
- https://optimuspharma.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Optimus Pharma is a Hyderabad-based CDMO delivering integrated contract development and manufacturing of small molecule drug substances and drug products, serving global pharmaceutical and biotech companies across 40+ countries with USFDA-inspected multi-unit facilities.
- Ownership category
- akta.pro rank
Optimus Pharma industry classification
Industry- Product category
- Pharmaceutical CDMO
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Small-Molecule API & Intermediates CDMO (HLAGABAA), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)
Keywords
Where Optimus Pharma is headquartered
LocationHeadquarters
- HQ city
- Hyderabad
- HQ country
- India
- HQ region
- Asia
Offices6 records
Markets served
Optimus Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- CDMO/CMO Services: Contract development and manufacturing services for drug substances and drug products. Revenue generated through development fees, manufacturing fees, and tech transfer services for pharmaceutical companies across the product lifecycle from clinical to commercial scale.
- API Manufacturing: Manufacturing and sale of Active Pharmaceutical Ingredients (APIs) and intermediates to pharmaceutical companies globally.
- Finished Dosage Formulation Manufacturing: Manufacturing of oral solids and semi-solids including tablets, capsules, creams, and ointments for commercial markets.
- R&D Services: Research and development services including analytical method development, validation, process optimization, and regulatory support.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Optimus Pharma product offering
Product offeringCore offering
Optimus Pharma operates as a Contract Development and Manufacturing Organization (CDMO) providing end-to-end integrated solutions from clinical development to commercial manufacturing of small molecule drug substances (APIs and advanced intermediates) and drug products. The company delivers custom synthesis, process scale-up, cGMP-compliant API manufacturing, formulation development, spray drying, micronization, multi-particulate pellet systems, and finished dosage formulation for global pharmaceutical innovators and generics manufacturers.
Differentiator
Problem solved
Functional benefit
Products and services
- Drug Substance Intermediates (CDMO) End-to-end CDMO support from clinical to commercial scale through custom synthesis, process scale-up, and cGMP/non-GMP manufacturing of advanced intermediates for global pharmaceutical clients.
- Drug Substance (API) CDMO Specialized small-molecule API development and manufacturing offering services across NCE/NDA development, custom APIs, and generic APIs for global pharma and biotech clients.
- Drug Product Intermediates Supply of drug product intermediates including pellets, micronized APIs, and spray-dried materials to support a range of formulation requirements for pharmaceutical customers.
- Drug Product (Finished Dosage Formulation) CDMO Development and manufacturing of oral solids, semi-solids, immediate-release, and controlled-release drug product formulations, including seamless technology transfers for existing client projects.
- Value Added Services Supporting CDMO offerings including analytical method development and validation, process optimization, regulatory and CMC services, and dedicated technology transfer services for client projects.
- API Product List Catalog of active pharmaceutical ingredients (APIs) manufactured by Optimus Pharma including generic and custom APIs supplied to pharmaceutical companies globally.
- FDF Products (Finished Dosage Formulations) Catalog of finished dosage formulations including tablets, capsules, pellets, and semi-solid forms manufactured at the USFDA-inspected Unit 4 FDF facility for commercial markets.
- Intermediates Catalog of advanced intermediates supplied for use in API manufacturing by pharmaceutical clients globally.
Quantifiable outcome
- Serving clients across 40+ countries globally
- +2 more outcomes
Companies that use Optimus Pharma
Customer profileNamed customers18 records
Segments3 records
Ideal customer profiles3 records
Optimus Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature8 records
Optimus Pharma partnerships and signals
Strategic signalScale indicators7 records
Recent moves6 records
Expansion highlights6 records
Optimus Pharma competitors and assessment
Company assessmentDirect peers
- Divis Laboratories: One of India's largest API and intermediates manufacturers with growing CDMO services for global pharma. Directly comparable to Optimus in small molecule API/intermediate manufacturing, regulatory accreditations and global customer mix.
- Laurus Labs: Indian-headquartered API and CDMO business serving global generic and innovator pharma customers. Highly comparable to Optimus in API/intermediate manufacturing, FDF capabilities and end-to-end CDMO positioning.
- Piramal Pharma Solutions: Global CDMO offering integrated drug substance and drug product services across multiple sites, including India. Direct competitor to Optimus in offering end-to-end small molecule development and manufacturing to innovator and generic customers.
- Syngene International: India-based CRO/CDMO providing development and manufacturing services to global pharma. Comparable to Optimus in serving innovator biotech customers, though Syngene has a stronger discovery/CRO tilt.
- Neuland Laboratories: Indian CDMO focused on small molecule APIs, intermediates and custom manufacturing for global pharma. Highly comparable scale and scope to Optimus's API/CDMO operations.
- Suven Pharmaceuticals: India-based CDMO providing API, intermediate and formulation development services to global pharma. Closely comparable to Optimus in service mix, scale and customer profile.
- Sai Life Sciences: Indian CRO-CDMO offering small molecule drug substance and drug product services. Overlaps with Optimus in serving innovator pharma customers and providing integrated development and manufacturing.
- Jubilant Pharmova (CDMO business): Indian pharma company with a sizable CDMO segment offering APIs, intermediates and sterile injectables manufacturing. Comparable to Optimus in API/intermediate capabilities and global customer mix.
- MSN Laboratories: Indian-headquartered API and finished dosage manufacturer with growing CDMO focus. Comparable to Optimus in integrated small molecule manufacturing and USFDA-inspected facilities.
Broad incumbents
- Aurobindo Pharma: Large Indian generic pharmaceutical company with significant API manufacturing and a growing CDMO offering. Overlaps with Optimus in API/intermediate supply and finished dosage manufacturing, but Aurobindo operates on a much larger scale and broader product portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Optimus Pharma social profiles
Digital presenceOptimus Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Optimus Pharma leadership team
Management profileNumber of profiles
Profiles6 records
Optimus Pharma subsidiaries and ownership
Company hierarchySubsidiaries2 records
Optimus Pharma funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Optimus Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Optimus Pharma
What does Optimus Pharma do?
Optimus Pharma operates as a Contract Development and Manufacturing Organization (CDMO) providing end-to-end integrated solutions from clinical development to commercial manufacturing of small molecule drug substances (APIs and advanced intermediates) and drug products. The company delivers custom synthesis, process scale-up, cGMP-compliant API manufacturing, formulation development, spray drying, micronization, multi-particulate pellet systems, and finished dosage formulation for global pharmaceutical innovators and generics manufacturers.
Is Optimus Pharma a public or private company?
Optimus Pharma is a private company. It is classified as private equity controlled and is currently operating.
When was Optimus Pharma founded?
Optimus Pharma was founded in 2004. It employs 51 to 100 people.
Where is Optimus Pharma based?
Optimus Pharma is headquartered in Hyderabad, India, in the Asia region.
How does Optimus Pharma make money?
Four revenue lines are on record. CDMO/CMO Services are the primary driver. The others are API Manufacturing, finished Dosage Formulation Manufacturing and R&D Services.
Who are Optimus Pharma's main competitors?
Direct peers on record are Divis Laboratories, Laurus Labs, Piramal Pharma Solutions, Syngene International, Neuland Laboratories, Suven Pharmaceuticals, Sai Life Sciences, Jubilant Pharmova (CDMO business) and MSN Laboratories. Aurobindo Pharma is listed as a broad incumbent.
Does Optimus Pharma have an API?
No public API is recorded for Optimus Pharma.
What industry is Optimus Pharma in?
Optimus Pharma's product category is Pharmaceutical CDMO. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAA, Small-Molecule API & Intermediates CDMO. Its NAICS code is 3254 and its SIC code is 2834.